Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 9:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 4,777 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: HIV Clear all
Withdrawn No phase listed Observational

Predictors of Time to Viremia With an Analytic Treatment Interruption

NCT03033017
View directory record Official record
Conditions
HIV
Interventions
Blood Testing
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
San Francisco, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Oct 26, 2026, 9:26 PM EDT
Withdrawn Phase 2 Interventional

Combination of an Investigational Cannabinoid and Methadone for HIV-associated Neuropathy

NCT00723918
View directory record Official record
Conditions
HIV-associated Neuropathy, Polyneuropathy
Interventions
SAB378, methadone, SAB placebo, Methadone placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
San Diego, California • Brooklyn, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2018 · Synced Oct 26, 2026, 9:26 PM EDT
Completed Not applicable Interventional

A Comparison of Fluconazole and Ketoconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems

NCT00002304
View directory record Official record
Conditions
Candidiasis, Esophageal, HIV Infections
Interventions
Ketoconazole, Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
41
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 26, 2026, 9:26 PM EDT
Not listed No phase listed Observational

An Antiretroviral Treatment Interruption (ATI) Study to Evaluate the Impact of Genetically Modified Autologous Cells (AGT103-T) to Suppress Human Immunodeficiency Virus Replication in the Absence of Antiretroviral Therapy

NCT05540964
View directory record Official record
Conditions
HIV
Interventions
Antiretroviral Therapy Interruption(ATI)
Other
Lead sponsor
American Gene Technologies International Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 26, 2026, 9:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Friendship Based HIV/STI (Sexually Transmitted Infections) Intervention for African American Females

NCT00109421
View directory record Official record
Conditions
Sexual Behavior, Sexually Transmitted Diseases, HIV Infections
Interventions
Project ÒRÉ
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
14 Years to 21 Years · Female only
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 26, 2026, 9:26 PM EDT
Completed No phase listed Observational

Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)

NCT03572335
View directory record Official record
Conditions
HIV Infections, Pulmonary Disease
Interventions
PFT's (pulmonary function testing)
Diagnostic Test
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 26, 2026, 9:26 PM EDT
Recruiting Not applicable Interventional

Community Health Workers And MHealth to ImProve Viral Suppression Plus (CHAMPS+)

NCT06472206
View directory record Official record
Conditions
HIV/AIDS
Interventions
CHW Sessions, CleverCap
Behavioral · Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Hobson City, Alabama • Opelika, Alabama • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 26, 2026, 9:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Healthy Lifestyles: A Home Based Physical Activity Intervention in Persons Living With HIV

NCT05896852
View directory record Official record
Conditions
HIV-1-infection, Metabolic Syndrome
Interventions
physical activity
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 26, 2026, 9:26 PM EDT
Completed Not applicable Interventional

Study of Home-Based Resistance and Strength Training in HIV-Infected Women

NCT00111332
View directory record Official record
Conditions
HIV Infections
Interventions
Progressive resistance and aerobic training
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2010 · Synced Oct 26, 2026, 9:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Preventing Chronic Disease: ActuaYa

NCT04088552
View directory record Official record
Conditions
Healthy Aging
Interventions
Go4Life-Physical Activity/Exercise Program "Workout to Go" 5, ActuaYa Educational Sessions
Other · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
50 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Oct 26, 2026, 9:26 PM EDT
Completed Phase 2 Interventional Results available

Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults

NCT00830804
View directory record Official record
Conditions
HIV-1 Infections
Interventions
Raltegravir, Darunavir/Ritonavir
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
22
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Oct 26, 2026, 9:26 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/B

NCT00007332
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC(2)120(B,MN)GNP (vCP1452), MN rgp120/HIV-1 and GNE8 rgp120/HIV-1
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2003
U.S. locations
17
States / cities
Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 26, 2026, 9:26 PM EDT
Recruiting Early Phase 1 Interventional

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

NCT04139304
View directory record Official record
Conditions
Plasmablastic Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
Interventions
Cyclophosphamide, Daratumumab, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Prednisone, Vincristine, Vincristine Sulfate
Drug · Biological
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
8
States / cities
Miami, Florida • Chicago, Illinois • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 26, 2026, 9:26 PM EDT
Completed Not applicable Interventional

Cell Phone Technology Targeting ART Adherence and Drug Use

NCT01884233
View directory record Official record
Conditions
HIV, Opioid Abuse
Interventions
Standard Care, Text Messaging CBT (TXT-CBT)
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 26, 2026, 9:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers

NCT00000884
View directory record Official record
Conditions
HIV Infections
Interventions
MN rgp120/HIV-1 and GNE8 rgp120/HIV-1, ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2000
U.S. locations
6
States / cities
Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 26, 2026, 9:26 PM EDT
Completed Phase 2 Interventional

Phase II Study of AGS-004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV

NCT00672191
View directory record Official record
Conditions
HIV Infections
Interventions
AGS-004
Biological
Lead sponsor
Argos Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2013 · Synced Oct 26, 2026, 9:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Linkage of Transgender Individuals to PrEP

NCT03191474
View directory record Official record
Conditions
HIV Seronegativity, Linkage
Interventions
T-POWr Intervention
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
Los Angeles, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Oct 26, 2026, 9:26 PM EDT
Completed Phase 3 Interventional

A Phase III Comparative Study of Dapsone / Trimethoprim and Clindamycin / Primaquine Versus Sulfamethoxazole / Trimethoprim in the Treatment of Mild-to-Moderate PCP in Patients With AIDS

NCT00000640
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Primaquine, Sulfamethoxazole-Trimethoprim, Dapsone, Clindamycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
32
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 26, 2026, 9:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector

NCT00801697
View directory record Official record
Conditions
HIV Infections
Interventions
DNA Vaccine, DNA Vaccine placebo, rAd35, rAd35 placebo, rAd5, rAd5 placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 26, 2026, 9:26 PM EDT
Completed Not applicable Interventional Results available

Assess and Adapt to the Impact of COVID-19 on CVD Self-Management and Prevention Care in Adults Living With HIV

NCT04661813
View directory record Official record
Conditions
HIV-1-infection, Hypertension
Interventions
EXTRA-CVD Virtual Care
Other
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Durham, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 26, 2026, 9:26 PM EDT
Completed Phase 2 Interventional

Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory AIDS-Related Lymphoma

NCT00005824
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, busulfan, cyclophosphamide, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 26, 2026, 9:26 PM EDT
Completed Phase 2 Interventional Results available

Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV

NCT02624180
View directory record Official record
Conditions
Coronary Artery Disease, Human Immunodeficiency Virus
Interventions
Colchicine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Oct 26, 2026, 9:26 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

An HIV Intervention for Black Men at Risk - The Enhanced Sexual Health Intervention for Men (ES-HIM)

NCT01641146
View directory record Official record
Conditions
HIV, Depression, Posttraumatic Stress Disorder
Interventions
Enhanced Sexual Health Intervention for Men (ES-HIM), Health Promotion (HP) Comparison Arm
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Male only
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
4
States / cities
Inglewood, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Oct 26, 2026, 9:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Combinations of Monoclonal Antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS Administered Via Intravenous Infusion in Healthy, HIV-uninfected Adult Participants

NCT03928821
View directory record Official record
Conditions
HIV Infections
Interventions
PGT121, PGDM1400, 10-1074, VRC07-523LS
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Oct 26, 2026, 9:26 PM EDT